ArticleProgress in biomaterials2020
Amphiphilic dextran-vinyl laurate-based nanoparticles: formation, characterization, encapsulation, and cytotoxicity on human intestinal cell line.
Article in Progress in biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glucan-Based Nanoparticles Empower Precision Cancer Immunotherapy: Design Strategies, Immune Reprogramming Mechanisms, and Clinical Translation Prospects.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dextran has been the model material for the therapeutic applications owing to its biodegradable and biocompatible properties, and the ability to be functionalized in variety of ways. In this study, the amphiphilic dextran was successfully synthesized through lipase-catalyzed transesterification between dextran and vinyl laurate. In aqueous solution, the produced dextran ester could self-assemble into spherical nanoparticles ("Dex-L NPs") with approximately 200-nm diameter, and could incorporate porcine placenta hydrolysate with 60% encapsulation efficiency. Furthermore, Dex-L NPs exhibited low cytotoxic effects on human intestinal cell line and, thus, were potentially safe for oral administration. Taken together, the findings illustrate the potential of the newly developed nanoparticles to serve as an efficient and safe drug delivery system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.